CTCBIO Inc
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergi… Read more
CTCBIO Inc (060590) - Net Assets
Latest net assets as of September 2025: ₩71.75 Billion KRW
Based on the latest financial reports, CTCBIO Inc (060590) has net assets worth ₩71.75 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩149.18 Billion) and total liabilities (₩77.43 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩71.75 Billion |
| % of Total Assets | 48.1% |
| Annual Growth Rate | 3.45% |
| 5-Year Change | -8.77% |
| 10-Year Change | -29.78% |
| Growth Volatility | 20.55 |
CTCBIO Inc - Net Assets Trend (2011–2024)
This chart illustrates how CTCBIO Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CTCBIO Inc (2011–2024)
The table below shows the annual net assets of CTCBIO Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩69.62 Billion | -7.72% |
| 2023-12-31 | ₩75.44 Billion | -21.38% |
| 2022-12-31 | ₩95.96 Billion | +12.88% |
| 2021-12-31 | ₩85.01 Billion | +11.40% |
| 2020-12-31 | ₩76.32 Billion | +2.11% |
| 2019-12-31 | ₩74.74 Billion | -13.97% |
| 2018-12-31 | ₩86.87 Billion | +17.42% |
| 2017-12-31 | ₩73.98 Billion | -18.61% |
| 2016-12-31 | ₩90.89 Billion | -8.32% |
| 2015-12-31 | ₩99.14 Billion | +15.97% |
| 2014-12-31 | ₩85.49 Billion | -7.30% |
| 2013-12-31 | ₩92.23 Billion | +47.80% |
| 2012-12-31 | ₩62.40 Billion | +39.23% |
| 2011-12-31 | ₩44.82 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to CTCBIO Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5538763021000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩12.09 Billion | 17.37% |
| Other Components | ₩112.92 Billion | 162.19% |
| Total Equity | ₩69.62 Billion | 100.00% |
CTCBIO Inc Competitors by Market Cap
The table below lists competitors of CTCBIO Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RS Public Company Limited
BK:RS-R
|
$58.53 Million |
|
AS Tallinna Vesi
F:A1T
|
$58.54 Million |
|
SDI Group plc
PINK:SDIIF
|
$58.54 Million |
|
Muthoot Microfin Limited
NSE:MUTHOOTMF
|
$58.56 Million |
|
Bank of Botetourt
PINK:BORTP
|
$58.52 Million |
|
Currency Exchange International Corp
PINK:CURN
|
$58.51 Million |
|
Hoang Quan Consulting Trading Service Real Estate Corp
VN:HQC
|
$58.51 Million |
|
Patriot One Technologies Inc
F:0PL
|
$58.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CTCBIO Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 75,444,321,160 to 69,620,419,960, a change of -5,823,901,200 (-7.7%).
- Net loss of 5,220,439,230 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.22 Billion | -7.5% |
| Other Changes | ₩-603.46 Million | -0.87% |
| Total Change | ₩- | -7.72% |
Book Value vs Market Value Analysis
This analysis compares CTCBIO Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.76x to 1.38x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩5283.66 | ₩4015.00 | x |
| 2017-12-31 | ₩4275.72 | ₩4015.00 | x |
| 2018-12-31 | ₩4563.01 | ₩4015.00 | x |
| 2019-12-31 | ₩3925.70 | ₩4015.00 | x |
| 2020-12-31 | ₩3673.67 | ₩4015.00 | x |
| 2021-12-31 | ₩3640.60 | ₩4015.00 | x |
| 2022-12-31 | ₩4013.72 | ₩4015.00 | x |
| 2023-12-31 | ₩3155.51 | ₩4015.00 | x |
| 2024-12-31 | ₩2911.92 | ₩4015.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CTCBIO Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.62%
- • Asset Turnover: 0.94x
- • Equity Multiplier: 2.21x
- Recent ROE (-7.50%) is above the historical average (-7.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 13.13% | 6.31% | 1.04x | 2.01x | ₩1.95 Billion |
| 2013 | 0.94% | 0.70% | 0.82x | 1.63x | ₩-8.35 Billion |
| 2014 | -4.10% | -2.87% | 0.75x | 1.90x | ₩-12.05 Billion |
| 2015 | 2.76% | 2.30% | 0.61x | 1.95x | ₩-7.17 Billion |
| 2016 | -3.01% | -2.22% | 0.65x | 2.08x | ₩-11.83 Billion |
| 2017 | -27.98% | -15.85% | 0.68x | 2.59x | ₩-28.10 Billion |
| 2018 | -10.43% | -6.55% | 0.72x | 2.21x | ₩-17.75 Billion |
| 2019 | -18.38% | -10.09% | 0.73x | 2.50x | ₩-21.21 Billion |
| 2020 | -25.50% | -14.96% | 0.73x | 2.32x | ₩-27.09 Billion |
| 2021 | -8.61% | -5.22% | 0.83x | 1.98x | ₩-15.82 Billion |
| 2022 | 7.04% | 4.09% | 0.88x | 1.96x | ₩-2.84 Billion |
| 2023 | -20.66% | -11.31% | 0.83x | 2.20x | ₩-23.13 Billion |
| 2024 | -7.50% | -3.62% | 0.94x | 2.21x | ₩-12.18 Billion |
Industry Comparison
This section compares CTCBIO Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CTCBIO Inc (060590) | ₩71.75 Billion | 13.13% | 1.08x | $58.53 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |